Hepatitis C virus (HCV), a member of the Flaviviridae family, is a positive-stranded RNA virus and is the major cause of both parenterally transmitted and sporadic non-A non-B hepatitis (Houghton, 1996) . Current therapy for HCV infection is effective in approximately 25% of patients and there is a clear clinical need for the development of new therapies for treatment of this disease (Bartenschlager, 1997) . The HCV genome encodes a single polyprotein (5′-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3′), which is processed by a combination of host and virally encoded proteinases into ten discrete proteins. The structural proteins C, E1, E2 and p7 are released from the HCV polyprotein by host-encoded proteinases (Grakoui et al., 1993) . The generation of the mature nonstructural (NS) proteins is achieved by the action of proteinases encoded by the virus genome. Cleavages at the NS3-4A, NS4A-4B, NS4B-5A and NS5A-5B junctions are mediated by a serine proteinase contained within the N-terminal 180 amino acid residues of the NS3 protein (Kwong, 1997) .
Introduction

Materials and Methods: Enzymology
HCV proteinase preparation
A plasmid encoding a fusion protein consisting of maltose binding protein, NS3 proteinase and NS4A was constructed as follows. Regions encompassing the NS3 proteinase domain (amino acids 1007-1219) and the NS4A protein (1658-1711) were isolated from plasmids described by Bartenschlager et al. (1993) and inserted into the pMAL-C2 vector using standard recombinant DNA techniques, including PCR amplification of the required sequences. Between the NS3 and NS4A domains, a linker region was constructed using synthetic oligonucleotides (amino acids 606-621), which encoded a linker of 12 glycine residues. The resulting plasmid was used to transform E. coli (strain MC1061) cells. The protein encoded by this plasmid will be referred to as MBP-NS3-4A. Overnight cultures of transformed cells were diluted 1 in 10 into Luria Bertani (LB) medium containing 100 µg ml -1 of ampicillin and grown at 37°C to an OD of 0.8 at 600nm. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 1 mM and incubation was continued for 3 h. Cells were collected by centrifugation, washed with PBS and pellets were stored at -70°C until required.
Cell pellets were resuspended in 50 mM Tris-HCl pH 7.5 containing 200 mM NaCl, 1 mM EDTA and 10 mM DTT using 20 ml of buffer for each litre of E. coli culture. The cells were broken by two passes through a French Pressure cell. The lysate was centrifuged for 30 min at 30 000×g to remove cell debris. The clarified extract was applied to an amylose resin column (5 ml resin per litre of E. coli) followed by washing using the lysis buffer. Bound protein was eluted using lysis buffer containing 10 mM maltose. The enzyme preparation was stored in aliquots at -70°C.
Assay of proteinase activity HPLC analysis. Enzyme assays using synthetic peptide substrates were performed in a total reaction volume of 100 µl at 25°C. The reaction buffer was 50 mM Tris-HCl pH 8.5 containing 1 mM DTT and 0.1% Triton X-100. The enzyme reactions were terminated by adding 10 µl of 10% trifluoroacetic acid (TFA) and samples (50 µl) were analysed on a Rainin Dynamax C18 column (Cat. No. R0083203F5, 4.6×50mm) using a gradient of acetonitrile:0.1% TFA for elution. Peak detection was accomplished by monitoring at 215 nm. Cleavage products were quantified by integration of chromatograms with respect to appropriate standard peptides. Kinetic parameters were calculated by non-linear least squares fitting the data using the program Enzfitter (Leatherbarrow, 1987) . To determine relative rates of hydrolysis for peptides, incubations were carried out using 400 µM peptide and incubation times were varied according to the efficiency of cleavage. Quantification of peptide cleavage was monitored by integration of chromatograms with respect to C-terminal cleavage fragments.
Fluorescence assay. A fluorescent substrate peptide based upon the NS4A-4B cleavage site, Dabcyl-DEMEEC~ASHE(γ-Edans)-NH 2 was prepared as a 20 mM stock solution in DMSO and was stored at -70°C. Reactions were carried out in a 96 well plate format (Perseptive Biosystems Cytoplate) using a final total volume of 200 µl. MBP-NS3-4A (0.7 nM final concentration) was added to the inhibitor solution (or DMSO) and, after 5 min, the reaction was initiated by adding 20 µl of fluorescent substrate to give a final substrate concentration of 10 µM. The final DMSO concentration did not exceed 4%. Fluorescence measurements were made at 25°C using a Cytofluor 4000 fluorimeter in kinetics mode (excitation 340 nm, emission 530 nm). IC 50 values were calculated as the concentration of inhibitor required to reduce the rate of fluorescence increase to 50% of the uninhibited control value.
Materials and Methods: Chemistry
Melting points were determined in open capillary tubes using a Büchi melting point apparatus and are uncorrected. Reactions were monitored by TLC performed on silica gel 60 F-254 plates (Merck). Flash chromatography was undertaken on silica gel (Sorbsil C60 40/60A). Preparative HPLC were performed on a Shimadzu LC-10A prep system. SSA denotes the solvent system 0.1% TFA in water and SSB denotes the solvent system 0.1% TFA in 70% acetonitrile, 30% water. Unless otherwise stated, all solvents were used as supplied. Evaporation of solvents was carried out under reduced pressure on a rotary evaporator. Mass spectra were obtained with a Kratos MS902 instrument in the normal electron impact (EI) mode or in fast atom bombardment (FAB) mode when fitted with a Kratos FAB source using a thioglycerol matrix. Mass spectra in the chemical ionization (CI) mode were recorded on a Finnigan 8430 instrument using isobutane as the reagent gas.
1 H-NMR spectra were recorded on either a Bruker AC-250, or a Bruker AC-400 spectrometer and chemical shifts were recorded in p.p.m. relative to tetramethylsilane (TMS). Elemental analyses were carried out on a PerkinElmer Model 240 instrument; where analyses are indicated only by symbols of the elements, the analytical results obtained for carbon, hydrogen and nitrogen were within 0.4% of the theoretical values. NMR data are available as supplementary information from the Editor-in-Chief on request.
Substrate peptides
Peptides were synthesized on a Milligen 9050 peptide synthesizer under continuous flow conditions employing FMOC chemistry. Either Pep Syn K resin with AM linker, or PEG. PS resin with PAL linker was used to obtain C-terminal amides. A fourfold excess of FMOC amino acids was used and the activation was carried out by 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (4-equivalents) in the presence of N-ethylmorpholine (8-equivalents). Resin cleavage conditions were TFA:phenol:EDTA:anisole (95:2.5:2.5:2.5) for 2 h at room temperature. The resin was removed by filtration, solvent evaporated and ether added to precipitate crude peptides. Purification was carried out by RP-HPLC on an ABI model 151A system using an aquapore octyl column (20 micron, 10×1000 mm). The elution gradient comprised 95% SSA-95% SSB over 15 minutes and the flow rate was 9 ml/min. The peptides were checked for purity by analytical RP-HPLC on the same system using an aquapore C-8 RP300 (7 micron, 30×4.6 mm) column with flow rate of 2 ml/min. The structures of the peptides were validated by mass spectrometry and 1 H-NMR.
Materials and Methods: Aldehydes
The aldehyde inhibitors in Table 1 were synthesized by one of four general methods, A to D.
General method A
This is exemplified by the synthesis of 2(RS)- [[N-[N-[N-[N-[N-[(3-carboxypropionyl 
(1) 1 M lithium aluminium hydride in tetrahydrofuran (10 ml, 10 mmol) was added to a solution of N,O-dimethyl (2) N2-[(9-fluorenyl)methoxycarbonyl]-N1-[1(S)-(dimethoxymethyl)-3-butynyl]-L-leucinamide (525 mg, 1.1 mmol) was dissolved in dichloromethane (20 ml) and piperidine (5 ml). The mixture was stirred at room temperature for 30 min. The mixture was evaporated to dryness and the residue was chromatographed on silica gel using firstly ethyl acetate:petrol (1:1) and then methanol:dichloromethane (1:9) for the elution. Evaporation of the dichloromethane solution gave N1-[1(S)-(dimethoxymethyl)-3-butynyl]-L-leucinamide as a gum which was used directly without further purification
namide was added to a solution of N-[(9-fluorenyl)methoxycarbonyl]-3-methyl-L-leucine (363 mg, 1.03 mmol), hydroxybenzotriazole (149 mg, 1.1 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (288 mg, 1.5 mmol) in dichloromethane (15 ml). The mixture was stirred for 18 h, then washed with 2 M hydrochloric acid and saturated sodium bicarbonate solution, dried over magnesium sulphate and evaporated to dryness. The residue was chromatographed on silica gel using ethyl acetate:petrol (1:2) for the elution to give N2- 
-aspartic acid and succinic acid monotert -butyl ester were then coupled in a manner analogous to steps (2) and (3) to afford N2- [N-[N-[N-[N-[3-(tertbutoxycarbonyl) 
-L-leucinamide (70 mg, 0.067 mmol) was stirred in a mixture of TFA (4 ml), dichloromethane (4 ml) and water (30 mg) at room temperature for 30 min. The solution was evaporated to dryness in a vacuum and the residue was chromatographed on silica gel using dichloromethane:methanol:acetic acid:water (60:13:2:2) for the elution. 
General method B
This is exemplified by the synthesis of 2(
(1) N,O-dimethyl-2(S)-(tert-butoxyformamido)butyrohydroxamate (370 mg, 2.5 mmol) was dissolved in anhydrous tetrahydrofuran (20 ml) under nitrogen and the solution was cooled to 0°C in an ice-bath. 1 M lithium aluminium hydride in tetrahydrofuran (1.5 ml, 1.5 mmol) was added and the mixture was stirred at 0°C for 10 min. Saturated aqueous potassium hydrogen sulphate (20 ml) was added and the mixture was stirred vigorously under nitrogen for 30 min at room temperature. The mixture was then diluted with diethyl ether (50 ml) and the organic layer was separated, dried over anhydrous magnesium sulphate and the solvent was evaporated. The residue was dissolved in a saturated methanolic hydrogen chloride solution (10 ml), stirred for 1 h, then diluted with toluene (50 ml) and evaporated to dryness to afford an oil that was used directly without further purification.
(2) The crude oil from above was dissolved in dichloromethane (10 ml) and
, 2-(3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride (58 mg, 0.3 mmol), 1-hydroxy-7-azabenzotriazole (41 mg, 0.3 mmol) and N-ethylmorpholine (350 mg, 3.0 mmol) were added. The mixture was stirred for 30 min then washed in sequence with saturated sodium bicarbonate solution and 2 M hydrochloric acid and dried over anhydrous magnesium sulphate. The solution was evaporated to dryness and the residue was chromatographed on silica gel using 4% methanol in dichloromethane for the elution. After trituration with diethyl ether N2- 
was dissolved in dichloromethane (3 ml), TFA (3 ml) and water (90 mg). The mixture was then stirred at room temperature for 30 min. The solution was diluted with toluene (20 ml) and the solvent was removed by evaporation. The resulting white solid was triturated with diethyl ether and filtered off. The solid was purified by RP-HPLC on a C18 Dynamax column (pore size 300 Å; column size 21.4 mm×50 mm). The elution gradient comprised 90% SSA, 10% SSB to 95% SSB, 5% SSA over 8.5 min. After 
General method C
This follows steps analogous to those of (1) and (2) of General method A, in which the Boc-protected Weinreb amide was converted to its corresponding dimethyl acetal, coupled to an Fmoc-protected amino acid and deprotected. This was then coupled to N- [N-[N-[N-[3-(tert- 
mic acid (fragment 3) followed by deprotection as described in steps (2) and (3) of General method B. (1) 2-Chlorotrityl resin (9 g, 1.35 mmol/g) was suspended and agitated in dichloromethane (100 ml). To this N-[(9-fluorenyl)methoxy-carbonyl]-L-glutamic acid 1-allyl ester (4.17 g, 10.2 mmol) was added followed by ethyldiisopropylamine (4.43 ml, 21 mmol) in dichloromethane (40 ml). After 25 min methanol (10 ml) was added and agitation was continued for a further 10 min. The resin was drained and washed three times with dichloromethane (100 ml), twice with N,N-dimethylformamide (100 ml), twice with isopropyl alcohol (100 ml), twice with N,N-dimethylformamide (100 ml), twice with isopropyl alcohol (100 ml), twice with methanol (100 ml) and twice with diethyl ether (100 ml). After drying 11 g of a pale brown resin was obtained (0.59 mmol/g loading estimated by quantification of dibenzofulvene at 301 nm).
General method D
This is exemplified by the synthesis of 2(RS
(2) The above resin (6 g, 3.45 mmol) was suspended in a 1:2 mixture of N,N-dimethylformamide and dichloromethane (60 ml) to which was added a mixture of 2-hydroxybenzotriazole (1.43 g, 10.35 mmol) and tetrakis-triphenylphosphine-palladium(0) (5.1 g, 2 mmol). After agitating for 3.5 h the resin was drained and washed five times with a 1:1 mixture of N,N-dimethylformamide and dichloromethane (60 ml), five times with N,Ndimethylformamide (60 ml) and five times with dichloromethane (60 ml).
(3) The resin was then suspended in a mixture of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (3.4 g, 10.4 mmol), 3,3-trifluoro-2(RS)-(dimethoxymethyl)propylamine hydrochloride (3.5 g, 9.7 mmol) and N-methylmorpholine (2.25 ml, 20 mmol) in N,N-dimethylformamide (50 ml). After agitating for 16 h the resin was drained and washed five times with N,N-dimethylformamide (60 ml), five times with dichloromethane (60 ml), twice with ethyl acetate (60 ml) and twice with diethyl ether (60 ml). After drying, the resin (6.7 g) was obtained as a pale brown solid (0.59 mmol/g loading estimated by quantification of dibenzofulvene at 301 nm).
(4) The resin (0.2 g, 0.12 mmol) was suspended and agitated in a 4:1 mixture of N,N-dimethylformamide and piperidine (7 ml). After 5 min the resin was drained, resusDesign of HCV NS3-4A proteinase inhibitors pended and again agitated with another of the above N,Ndimethylformamide and piperidine mixture (7 ml) for a further 5 min. Following this the resin was drained and washed five times with N,N-dimethylformamide (10 ml).
(5) The resin was then suspended in a solution of N-[(9-fluorenyl)methoxycarbonyl]-L-valine (0.24 g, 0.72 mmol) in N,N-dimethylformamide (3.4 ml) and then a mixture of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.19 g, 0.6 mmol) and N-methylmorpholine (0.12 g, 1.2 mmol) dissolved in N,N-dimethylformamide (3.4 ml) was added. After agitating for 1 h the resin was drained and washed five times with N,Ndimethylformamide (10 ml).
-aspartic acid and tert-butyl hydrogen succinate were then coupled in a manner analogous to steps (4) and (5).
A 19:1 mixture of TFA and water (6 ml) was added to the resin followed by agitation for 10 min. The resin was then filtered from the mixture and agitated for a further 10 min with the 19:1 mixture of TFA and water (6 ml). The combined TFA and water mixtures were then evaporated. Following preparative HPLC (C18 300A Dynamax column eluting with acetonitrile: Except where stated, all fragments were synthesized as exemplified for the synthesis of N- [N-[N-[N-[N-[3-(tertbutoxycarbonyl) 
(1) A solution of L-leucine benzyl ester p-toluenesulphonic acid salt (25 g, 63.6 mmol), N-(tert-butoxycarbonyl)-3-methyl-L-valine (14.69 g, 63.6 mmol), 1-hydroxybenzotriazole (9.73 g, 63.6 mmol), N-ethylmorpholine (7.32 g, 63.3 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (12.21 g, 63.6 mmol) in dichloromethane (500 ml) was stirred at room temperature overnight. The solution was washed with water, sodium hydrogen carbonate solution, 2M hydrochloric acid and saturated sodium chloride solution and dried over anhydrous magnesium sulphate. Evaporation gave N-[(N-tert-butoxycarbonyl)-3-methyl-L-valyl]-L-leucine benzyl ester (21.65 g) as an oil which was used in the next step without further purification. MS m/e 435 (M+H) + .
(
-L-leucine benzyl ester (9.74 g, 22.4 mmol) in TFA (25 ml) and dichloromethane (50 ml) was stirred at room temperature for 30 min. The solvent was removed by evaporation and toluene (50 ml) was added. Evaporation gave N-(3-methyl-L-valyl)-L-leucine benzyl ester as an oil, which was used in the next step without further purification.
(3) A solution of this oil, N-(9-fluorenylmethoxycarbonyl)-2-methyl-L-phenylalanine (9 g, 22.4 mmol), 1-hydroxybenzotriazole (3.43 g, 22.4 mmol), N-ethylmorpholine (3.87 g, 33.66 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (4.31 g, 22.4 mmol) in dichloromethane (100 ml) was stirred at room temperature overnight. The solution was washed with water, sodium hydrogen carbonate solution, 2 M hydrochloric acid and saturated sodium chloride solution and dried over anhydrous magnesium sulphate. Evaporation and chromatography on silica gel using 30% ethyl acetate in petroleum ether (b.p. 40-60°C) for the elu-
-L-leucine benzyl ester (10 g, 13.95 mmol) in piperidine (30 ml) and dichloromethane (120 ml) was stirred for 30 min at room temperature. The solvent was removed by evaporation and the residue was chromatographed on silica gel using firstly 20% ethyl acetate in hexane and then 10% methanol in dichloromethane for the elution. Evaporation gave N-
benzyl ester (6.9 g) in the form of an oil, which was used in the next step without further purification.
butyl-L-α-aspartic acid and tert-butyl hydrogen succinate were then coupled in a manner analogous to steps (3) and (4) to afford N- [N-[N-[N-[N-[3-(tert- 
l]-L-leucine benzyl ester (6.8 g, 6.75 mmol) in dimethylformamide (200 ml) was hydrogenated over 10% palladium:carbon (600 mg) for 1 h. The catalyst was removed by filtration and the filtrate was evaporated to give crude product (15 g), which was chromatographed on silica gel using 10-15% methanol in dichloromethane for the elution to give N- [N-[N-[N-[N-[3-(tert-butoxycarbonyl) 
acid (fragment 3), the procedure followed that indicated for fragment 1 except for the final hydrogenolysis which employed palladium black in place of palladium on charcoal.
A
benzyl ester (4.22 g, 4.5 mmols) in methanol (95.6 ml) and formic acid (4.4 ml) was added to palladium black (1 g) under a nitrogen atmosphere with ice cooling. The mixture was stirred for 2 h at room temperature then filtered, evaporated and re-evaporated with toluene. The residue was tritrated with diethyl ether:40-60 petrol (1:1) and 
Materials and Methods: Boronic Acids
All boronic acids in Table 2 were synthesized via the method exemplified for the synthesis of 1(
]amino]-3-butenylboronic acid (1:1 mixture of diastereoisomers) (59).
(1) 2-(dichloromethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2 g, 9.48 mmol) was dissolved in tetrahydrofuran (30 ml) and the solution was cooled under a nitrogen atmosphere to -78°C. 1 M Allylmagnesium bromide (9.5 ml, 9.5 mmol) was added dropwise and the solution was stirred at room temperature for 18 h. The solution was partitioned between ethyl acetate, saturated sodium chloride solution and 2 M hydrochloric acid solution. The aqueous layer was extracted with ethyl acetate and the organic layers were combined and dried over anhydrous sodium sulphate. After filtration and evaporation the oil obtained was distilled to give 2-(1(RS)-chloro-3-butenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.45 g); b.p. 53°C/0.4 mm Hg.
(2) 1 M Lithium bis(trimethylsilyl)amide in tetrahydrofuran (6.6 ml, 6.6 mmol) was added dropwise to a solution of 2-(1(RS)-chloro-3-butenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.43 g, 6.6 mmol) in tetrahydrofuran (20 ml) under nitrogen at -78°C. The solution was then stirred overnight at room temperature. The solvent was removed by evaporation and the residue was taken up in diethyl ether. Insoluble material was removed by filtration and the filtrate was cooled to 0°C. TFA (1.5 ml, 19.8 mmol) was added and the solution was stirred at 0°C for 30 min. The resulting precipitate was filtered off and dried to give α-(RS)-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-methylamine trifluoroacetate (0.5 g), which was used in the next step without further purification. 
(3) N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-α-aspartyl]-O-tert-butyl-L-α-glutamyl]-
2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucine
(fragment 1, 0.25 g, 0.27 mmol) was dissolved in dimethylformamide (4 ml) and dichloromethane (4 ml). N-methylmorpholine (0.15 ml, 1.6 mmol) was added and the solution was cooled to -15°C under a nitrogen atmosphere. Isobutyl chloroformate (50 mg, 0.38 mmol) was added and the solution was stirred for 10 min at -15°C. α-(RS)-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-methylamine trifluoroacetate (0.1 g, 0.32 mmol) was added and the mixture was stirred at room temperature for 18 h. After evaporation the residue was partitioned between ethyl acetate and 2 M hydrochloric acid. The organic layer was washed with 2 M hydrochloric acid, water and saturated sodium chloride solution and then dried over anhydrous sodium sulphate. (4) N2- [N-[N-[N-[N-[3-(tert-butoxycarbonyl) 
]-L-leucinamide (0.236 g, 0.215 mmol) was dissolved in water (1.5 ml), TFA (13.5 ml) and dichloromethane (7 ml) and the solution was stirred at room temperature for 1 h and then left to stand at 4°C for 18 h. The solution was then diluted with toluene and evaporated. The residue was triturated with diethyl ether and the resulting solid was filtered off. The solid was purified by RP-HPLC on a Dynamax C18 column (5 micron, 300Å, 21.4 mm×50 mm). The elution gradient comprised 95% SSA 5% SSB to 95% SSB 5% SSA over 6 min and, after lyophilization, 
Results
Enzyme characterization
To develop in vitro enzyme assays to allow evaluation of enzyme activity and inhibitor testing, the NS3 proteinase was expressed in E. coli as a fusion protein consisting of maltose binding protein, NS3 proteinase and NS4A. The NS4A was covalently linked to NS3 via a 12 residue glycine linker (see Materials and Methods). The protein expressed in E. coli was purified from soluble extracts of E. coli by amylose affinity chromatography. The isolated protein was tested for activity using a dodecapeptide substrate based on the NS4A-4B cleavage site of the HCV polyprotein (Succ-DEMEEC~ASHLPY-NH 2 , 1) and subsequent HPLC analysis of reactions. Optimal buffer conditions for peptide cleavage were found to require 0.1% Triton X-100 and 1 mM DTT at pH 8. Figure 1 . Solution synthesis of aldehydes -General methods A, B and C buffer conditions gave a k cat =0.06 s -1 and K m =200 µM. These kinetic data were consistent with those published on full length NS3 proteinase by Zhang et al. (1997) and Gallinari et al. (1998) . This HPLC-based assay system was used to evaluate the relative cleavage efficiencies of substrate peptides in which amino acid substitutions or truncations had been made (see later sections). To facilitate inhibitor potency determinations a fluorescencebased assay was also developed using an internally quenched fluorogenic substrate, Dabcyl-DEMEEC-ASHE(γ-Edans)-NH 2 . Incubation of this peptide with the enzyme resulted in an increase in fluorescence intensity, which could be monitored in a continuous mode in a 96 well plate format allowing evaluation of inhibitors.
Chemistry
The synthesis of the aldehyde inhibitors (Figures 1 to 3 ) started with the Boc-derivative of the amino acid corresponding to P 1 . Conversion of these to the Weinreb amides followed by lithium aluminium hydride reduction (Fehrentz & Castro, 1983; Nahm & Weinreb, 1981) and treatment with a saturated solution of hydrogen chloride in methanol afforded the corresponding amino acetals as the hydrochloride salts. These were then elaborated to the final product by one of several general methods; general method A, stepwise coupling of Fmoc-protected amino acids; general method B, coupling a pre-formed fragment corresponding to P 6 -P 2 (fragments 1 and 2); general method C, coupling of the Fmoc-protected P 2 amino acid followed by coupling of a fragment corresponding to P 6 -P 3 (fragment 3); general method D, coupling to Fmocglutamic acid attached to chlorotrityl resin via its δ-carboxyl and further elaborated using solid phase Fmoc methodology.
All amino acid couplings employed Fmoc-protected amino acids except the first step of the synthesis of the fragments. These employed the benzyl ester of the C-terminal amino acid, which was coupled to a Boc-protected amino acid. Removal of the Boc group using TFA afforded the dipeptide as its TFA salt. This approach avoided the Figure 2 . General synthesis of fragments formation of the free amine and suppressed the potential diketopiperazine formation. The dipeptide was then extended to the desired length using Fmoc methodology and hydrogenolysis afforded the required fragment. Coupling to the C termini of these fragments then proceeded without racemization of the potentially labile chiral centre.
The boronic acids were synthesized using the methodology of Matteson (1989) followed by coupling to a mixed anhydride of fragment 1 (Figure 4 
Discussion
The amino acid sequence of the proteolytic region of the NS3 protein revealed the catalytic serine 139 , histidine 56 and aspartic acid 79 residues within sequence motifs characteristic of classical serine proteinases such as elastase (Greer, 1981 (Greer, , 1990 . It therefore seemed likely that the NS3-4A proteinase would have the same basic β-barrel core structure as these and would bind and process its substrates in a similar manner (subsequent X-ray studies by ourselves and others have confirmed this. See Kim et al., 1996; Love et al., 1996; Yan et al., 1998) .
The design of substrate-based inhibitors is well known for this class of enzymes (Edwards & Bernstein, 1994) and this approach appeared attractive for the HCV NS3-4A proteinase. The general structure of these inhibitors comprises several non-prime side residues from one of the cleavage sites of the substrate in which the carbonyl of the scissile amide bond is replaced by an electrophile (see Figure 5 ). This electrophile binds reversibly to the catalytic serine.
Our strategy for the design of inhibitors was based upon the use of substrate studies to determine the minimal sequence required for substrate recognition, identify suitable replacements for cysteine at P 1 and guide the initial optimization of the P 2 , P 3 and P 4 residues.
The sites of the HCV polyprotein cleaved by NS3-4A proteinase are shown in Figure 6 . The three intermolecular cleavage sites NS4A-4B, NS4B-5A and NS5A-5B have cysteine at P 1 , whereas the intramolecular cleavage site NS3-4A, has threonine. All four cleavage sites have acidic residues (aspartic or glutamic acid) at P 6 and small residues (alanine or serine) at P 1 ′. There appears to be little homology at the other positions.
Determining the minimal sequence required for substrate recognition
In order to determine the minimum number of non-prime side residues required by the NS3-4A proteinase for efficient substrate cleavage, a series of N-terminal truncations was made to the NS4A-4B synthetic substrate, 1. The extent of processing of these substrates after incubation with MBP-NS3-4A was then measured (Table 3) .
These data show a dramatic reduction in processing upon removal of the P 6 aspartic acid. Extending the substrate beyond this point had little effect. This acidic residue is conserved at the P 6 position in all the NS3-4A proteinase cleavage sites and these data demonstrate it is vital for efficient proteolytic activity. This residue was therefore incorporated into our inhibitors.
A study of the structural features affecting the processing of synthetic substrates was undertaken since it seemed likely that this might be predictive of the potency of the inhibitors derived from them. This approach had the advantage that the substrates could be rapidly synthesized by employing solid phase technology.
Determining a suitable replacement for cysteine
The P 1 positions of the intermolecular cleavage sites of NS3-4A proteinase are occupied by cysteine and its nucleophilic side-chain is incompatible with an electrophile attached to its C terminus. In order to identify suitable replacements for this moiety, analogues of NS4A-4B substrate, 1, were synthesized in which this cysteine was replaced by a range of small, lipophilic amino acids. The extent of processing of these substrates (Table 4) after incubation with MBP-NS3-4A was then measured and this identified aminobutyric acid, allylglycine, propargylglycine and trifluoroaminobutyric acid as replacements (substrates 8 to 11 respectively). Inhibitors based upon the minimal substrate information and these cysteine replacements were then prepared. The absolute activity of these inhibitors (14 to 17) was modest, but we were encouraged to see that their relative potency reflected the relative processing of the substrates from which they were derived, thereby validating our approach. Figure 5 . Substrate-based inhibitors of serine proteinases Optimization of the P 2 , P 3 and P 4 residues Enhancement of the activity of these inhibitors began by optimizing the side-chains of the P 2 , P 3 and P 4 residues and studies on the NS4A-4B substrate, 1, were again used to guide our exploration of these residues.
Amino acids with a representative range of properties were individually introduced at each position. Thus, alanine (small lipophilic), phenylalanine (large lipophilic), aspartic acid (acidic) and lysine (basic) were introduced, as well as those amino acids from the equivalent positions in the NS4B-5A and NS5A-5B cleavage sites. The extent of processing of these substrates was then determined (Table 5) .
These data showed that phenylalanine and proline were well tolerated at P 2 (compounds 21 and 22), valine (present in the NS5A-5B cleavage site) was well tolerated at P 3 (compound 28) and phenylalanine was well tolerated at P 4 (compound 32). These residues were then introduced into the inhibitors and used as our starting point for further optimization (Tables 6 and 7) .
Optimization of P 2 and P 4 was carried out on inhibitor 16, which had propargylglycine at P 1 . When phenylalanine was introduced into 16 at P 2 the activity of the inhibitor improved from 23 µM to 5 µM. Substitution of this by leucine then provided a further improvement in activity to 2 µM. This preference for γ-branched amino acids at P 2 has also been observed by Ingallinella et al. (1998) Succ-Asp-Glu-P 4 -Glu-P 2 -HN CHO Table 5 . Optimization of the P 2 , P 3 and P 4 residues in substrates Succ-Asp-Glu-P 4 -P 3 -P 2 -Cys~Ala-Ser-His-Leu-Pro-Tyr-NH 2 Relative Compound P 4 P 3 P 2 cleavage (%)* donating groups into the para-position of the aromatic ring (compounds 36-39) had little effect on the potency, but introduction of a methyl group into the ortho-position resulted in a net four-to fivefold enhancement in activity over the original methionine. Optimization of P 3 was carried out on inhibitor 17, which had trifluoroaminobutyric acid at P 1 . Substitution of valine into 17 at P 3 provided an immediate enhancement in activity to 3 µM. Ingallinella et al. (1998) have also observed a preference for β-branched amino acids at this position. Further substitution onto the isopropyl group in the valine side chain had little effect, but increasing the β-branching to tertbutylglycine provided 45 with an IC 50 =1 µM. X-ray studies of substrate based inhibitors of elastase (Navia et al., 1989) show they bind in an extended conformation and these inhibitors are expected to bind to HCV NS3-4A proteinase in a similar manner. The β-branching in tertbutylglycine most likely restricts part of the backbone of the inhibitor to an extended conformation prior to its binding to the NS3 protein. The increase in potency might therefore be due to the reduction in loss of entropy by the inhibitor upon binding to the NS3 protein.
Combination of the modifications and further optimization of P 1
When the modifications to P 2 , P 3 and P 4 were combined, their enhancements in activity were essentially additive and provided 46 and 47 with IC 50 values against the HCV NS3-4A proteinase of 64 nM and 180 nM, respectively.
The P 1 binding site of serine proteinases is responsible for defining its selectivity and for a significant amount of binding. For example, human neutrophil elastase preferentially accepts a small lipophilic P 1 residue such as valine (Edwards & Bernstein, 1994) , whilst chymotrypsin prefers large lipophilic residues such as phenylalanine (Angelastro et al., 1990) . Trypsin and thrombin on the other hand prefer basic residues (Kettner et al., 1990) . A re-examination of this position within the context of our more potent inhibitors was therefore undertaken (Table 8) .
Removing the fluorines from 46 caused a significant reduction in activity to 540 nM (compound 48) but extension of the alkyl chain to butyl reclaimed all the lost activity (IC 50 =65 nM, compound 50). This trend of improvement in activity with extension of alkyl chain was also observed by Llinàs-Brunet et al. during their studies (1998) . The allylglycine analogue, 52, was similarly active and superior to both the propargyl and the fully saturated, propyl analogues, 47 and 49, respectively. Further extension (compound 51) was detrimental. Since a range of alkylglycines had successfully been introduced into the P 1 position, S-alkylcysteines were also expected to be well tolerated. This hypothesis proved to be valid and both S-methylcysteine and S-butylcysteine Significantly larger groups such as Sbenzylcysteine and S-(3-phenylpropyl)-cysteine (compounds 55 and 56) were also tolerated, albeit with a slight reduction in activity. From these results it appears only the first 3-4 atoms of the side chain of P 1 contribute to binding to the proteinase. Atoms beyond the δ-position probably point into solution.
Boronic acids
Although aldehydes provided potent inhibitors of the NS3-4A proteinase in vitro, their expected rapid metabolism would preclude them from further development. Boronic acids are a class of electrophile that exhibits potent serine proteinase activity in vitro (Kettner & Shenvi, 1984; Edwards & Bernstein, 1994) and in vivo (for example, Kinder et al., 1992) . Several boronic acids analogous to our optimized aldehydes were therefore synthesized. These exhibited a modest improvement in activity and the boroaminobutyric acid and boro-allylglycine, derivatives 57 and 59, were the most potent inhibitors of HCV NS3-4A proteinase synthesized (Table 9) .
Conclusions
This report has demonstrated how a detailed study of the substrate specificity of NS3-4A proteinase was used to assist the optimization of inhibitors of this enzyme. An improvement in activity of almost 1000-fold over the initial leads 16 and 17 (IC 50 =23 and 20 µM, respectively) to the optimized aldehydes (for example, 46, 50 and 52, IC 50 =64, 65 and 90 nM, respectively) and boronic acids (for example 57 and 59 IC 50 =38 and 34 nM respectively) was achieved. These are the most potent inhibitors of HCV NS3-4A proteinase containing an electrophile reported to date. Our studies to further enhance the activity of these inhibitors against HCV NS3-4A proteinase and their selectivity over important human serine proteinases such as elastase will be reported in due course.
